Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)

Mizuho analyst Uy Ear reiterated an Outperform rating and $195.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)

The analyst comments "This morning, Sarepta reported encouraging additional data from the Phase 3 EMBARK trial that adds to Elevidys' use case: (1) Older placebo crossover patients treated with Elevidys, in Part 2, demonstrated statistically significant improvements across key functional endpoints including NSAA (+2.34 points; p<0.0001), TTR (-2.7 seconds; p<0.0001), and 10MWR (-1.07 seconds; p=0.001) at one year compared to matched external controls; and (2) 2-year follow-up data don't appear to show an attenuation in Elevidys' effect (a key concern given cell division leading to potential gene therapy dilution) as patients Part 1 treated patients showed consistent, sustained expression of Elevidys micro-dystrophin and benefit in functional endpoints, and 2-Year skeletal muscle MRI data demonstrated minimal muscle pathology progression and were consistent with functional benefits observed. All studied patients remained ambulatory at year 2. Importantly, no new safety signals were identified. We reiterate our OP and $195 PT."

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $116.46 yesterday.

You May Also Be Interested In

• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• Morgan Stanley Resumes OMV AG (OMV:AV) (OMVKY) at Equalweight
• Raymond James Upgrades Aecon Group (ARE:CN) (AEGXF) to Outperform